Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy
- PMID: 17275908
- DOI: 10.1016/j.ophtha.2006.07.047
Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy
Abstract
Objective: To evaluate the hemostatic effects of intravitreal infusion of 10% C3F8 in patients undergoing diabetic vitrectomy on the occurrence of early postoperative recurrent vitreous hemorrhage.
Design: Prospective, randomized, observational case series.
Participants: Sixty-one eyes (59 patients) that underwent primary pars plana vitrectomy for complications of proliferative diabetic retinopathy from September 2004 to April 2005, with postoperative retinal reattachment > or = 3 months and follow-up > 6 months were enrolled.
Methods: Sixty-one cases were randomly divided into either group 1 (intravitreal 10% C3F8 infusion at the end of surgery) or group 2 (no intravitreal gas). Ultrasound biomicroscopy (UBM) examination of the 3 sclerotomy sites was performed at > or = 2 months postoperatively. Demographic data, history, intraoperative findings, and management of recurrent vitreous hemorrhage were recorded.
Main outcome measures: Initial time to vitreous clearing (ITVC), percentage of prolonged ITVC (> 5 weeks), and early (< or = 4 weeks) versus late (> 4 weeks) manifest postoperative recurrent vitreous hemorrhage in groups 1 and 2 were compared to determine the effects of 10% C3F8 on prevention of early recurrent vitreous hemorrhage. Multiple logistic regression analyses were performed to examine risk factors related to early recurrent vitreous hemorrhage.
Results: Group 1 ITVC was 13.2+/-9.6 days, and group 2 ITVC was 11.3+/-11.1 days (P = 0.26). Prolonged ITVC (> 5 weeks) in each group was 1/31 (3.2%) and 2/30 (6.7%; P = 0.53). Early manifest recurrent vitreous hemorrhage rates in groups 1 and 2 were 0/31 (0%) and 5/30 (16.7%), respectively (P = 0.02). Early manifest recurrent hemorrhage plus prolonged ITVC in the 2 groups were 1/31 (3.2%) and 7/30 (23.3%), respectively (P = 0.02). The incidences of elevated intraocular pressure, iris neovascularization, and significant cataract formation among the 2 groups were too low to detect statistical significance. No evidence of fibrovascular ingrowth was found by UBM examination in either group. Multiple logistic regression analyses in non-gas-infused cases showed that an increased extent of membrane peeling raised the possibility of significant early vitreous rebleeding.
Conclusions: Intraocular tamponade with 10% C(3)F(8) may be a useful adjunct to vitrectomy for proliferative diabetic retinopathy in the reduction of early postoperative recurrent vitreous hemorrhage.
Similar articles
-
Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy.Am J Ophthalmol. 2008 Aug;146(2):211-217. doi: 10.1016/j.ajo.2008.04.028. Epub 2008 Jun 11. Am J Ophthalmol. 2008. PMID: 18547539
-
The effect of adjunctive intravitreal bevacizumab for preventing postvitrectomy hemorrhage in proliferative diabetic retinopathy.Ophthalmology. 2011 Nov;118(11):2218-26. doi: 10.1016/j.ophtha.2011.03.036. Epub 2011 Jul 2. Ophthalmology. 2011. PMID: 21724263 Clinical Trial.
-
Intravitreal triamcinolone acetonide injection at the end of vitrectomy for diabetic vitreous hemorrhage: a randomized, clinical trial.Retina. 2008 Oct;28(9):1241-6. doi: 10.1097/IAE.0b013e31817d5be3. Retina. 2008. PMID: 18626423 Clinical Trial.
-
Management of proliferative diabetic retinopathy.Compr Ophthalmol Update. 2007 Sep-Oct;8(5):245-56. Compr Ophthalmol Update. 2007. PMID: 18201511 Review.
-
[Vitreous hemorrhage: attitudes in therapy, vitrectomy].Diabete Metab. 1993 Sep-Oct;19(5):436-40. Diabete Metab. 1993. PMID: 8056123 Review. French.
Cited by
-
Management of Complications and Vision Loss from Proliferative Diabetic Retinopathy.Curr Diab Rep. 2021 Sep 3;21(9):33. doi: 10.1007/s11892-021-01396-2. Curr Diab Rep. 2021. PMID: 34477996 Review.
-
Association between stress hyperglycemia ratio and diabetic retinopathy progression and surgical prognosis: insights from NHANES 2005-2018 and clinical cohort study.Diabetol Metab Syndr. 2025 Jul 16;17(1):271. doi: 10.1186/s13098-025-01839-w. Diabetol Metab Syndr. 2025. PMID: 40671060 Free PMC article.
-
Neovascular glaucoma after vitrectomy in patients with proliferative diabetic retinopathy.Medicine (Baltimore). 2017 Mar;96(10):e6263. doi: 10.1097/MD.0000000000006263. Medicine (Baltimore). 2017. PMID: 28272234 Free PMC article.
-
The adjunctive use of pre-operative intravitreal bevacizumab in the setting of proliferative diabetic retinopathy.Saudi J Ophthalmol. 2016 Oct-Dec;30(4):217-220. doi: 10.1016/j.sjopt.2016.10.001. Epub 2016 Oct 29. Saudi J Ophthalmol. 2016. PMID: 28003778 Free PMC article.
-
Sulfur Hexafluoride 20% versus Lactated Ringer's Solution for Prevention of Early Postoperative Vitreous Hemorrhage after Diabetic Vitrectomy.J Ophthalmic Vis Res. 2010 Apr;5(2):105-9. J Ophthalmic Vis Res. 2010. PMID: 22737339 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous